A Real Life Study to Evaluate the Real World Efficacy and Safety of Bortezomib Based Therapy for Induction Treatment Followed by Ixazomib in Combination with Dexamethasone as Maintenance Therapy in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients
Latest Information Update: 22 Jul 2020
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Doxorubicin liposomal (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association.